University of Luxembourg

BIOMARKER FOR PREDICTION OF RECURRENCE IN COLORECTAL CANCER PATIENTS

Posted by Lidia from University of LuxembourgResponsive · Innovative Products and Technologies · Luxembourg

Summary of the technology

Approximately 20% of colorectal cancer patients with stage II colorectal cancer experience relapse of the disease. Current clinical-pathologic stratification factors do not allow clear identification of these high-risk patients. The invention is a powerful prognostic biomarker in colorectal cancer, especially in early stages (stages I and II), which might help stratifying patients with stage II for adjuvant chemotherapy.

The invention provides a gene expression classifier that distinguishes patients with low or high risk of disease relapse in colorectal cancer and that might be used in the clinics to help clinicians identify high-risk patients and choose the most appropriate treatment for a given patient.

University of Luxembourg

ADVANTAGES

• Cost efficient and easy-to-use solution for colon cancer management
• Identification of patients at high-risk in stage II MMR-P patients
• Prevent overtreatment with chemotherapy
• Improved prognostic accuracy

TECHNOLOGY AND IP STATUS

The invention has been implemented and tested in several public available databases containing clinical data on colorectal cancer patients.

Patent: LU100371 NOVEL BIOMARKERS FOR CANCER DIAGNOSIS, PREDICTION OR STAGING Filling date: 14-Aug-2017

Technology Owner

University of Luxembourg

Research & Technology Organization

Related keywords

  • Applications for Health
  • Medicine, Human Health
  • Cytology, Cancerology, Oncology
  • Gene - DNA Therapy
  • Gene Expression, Proteom Research Technology
  • Medical/health
  • Gene Expression, Proteom Research Market
  • Medical Health related
  • Therapeutic
  • biomarker
  • chemotherapy
  • colorectal cancer
  • prognostic biomarker

About University of Luxembourg

Research & Technology Organization from Luxembourg

The University of Luxembourg, founded in 2003, is a European research university with a distinctly international, multilingual and interdisciplinary character. It is a modern institution with a personal atmosphere, close to European institutions, innovative companies and the financial place.

With nearly 6,200 students and about 1,700 employees from all over the globe, the University offers a unique mix of international excellence and national relevance, delivering knowledge for society and businesses. The University has three faculties and three interdisciplinary centers:

• The Faculty of Science, Technology and Communication (FSTC)
• The Faculty of Law, Economics and Finance (FDEF)
• The Faculty of Language and Literature, Humanities, Arts and Education (FLSHASE)
• The Interdisciplinary Centre for Security, Reliability and Trust (SnT)
• The Luxembourg Centre for Systems Biomedicine (LCSB)
• Luxembourg Centre for Contemporary and Digital History (C²DH)

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.